keyword
MENU ▼
Read by QxMD icon Read
search

biomarkers bladder cancer

keyword
https://www.readbyqxmd.com/read/27925173/potential-of-long-non-coding-rnas-in-cancer-patients-from-bio-markers-to-therapeutic-targets
#1
REVIEW
Subash Chandra Gupta, Yashoda Nandan Tripathi
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a bio-marker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer, and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential...
December 7, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27907054/dapk-promoter-methylation-and-bladder-cancer-risk-a-systematic-review-and-meta-analysis
#2
Lihe Dai, Chong Ma, Zhensheng Zhang, Shuxiong Zeng, Anwei Liu, Shijie Tang, Qian Ren, Yinghao Sun, Chuanliang Xu
BACKGROUND: Methylation of tumor suppressor gene promoter leads to transcription inactivation and is involved in tumorigenesis. Several studies demonstrate a potential association between the Death-Associated Protein Kinase (DAPK) gene promoter methylation and bladder cancer risk, tumor stage and histological grade. Due to inconsistent results of these studies, we performed this meta-analysis to ascertain the association. METHODS: Studies were retrieved from the PubMed, Embase, Web of Science and the Cochrane Library databases...
2016: PloS One
https://www.readbyqxmd.com/read/27904689/mir-4295-promotes-cell-growth-in-bladder-cancer-by-targeting-btg1
#3
Yong-Hao Nan, Jun Wang, Yao Wang, Peng-Hao Sun, Yu-Ping Han, Li Fan, Kai-Chen Wang, Fu-Jun Shen, Wei-Hua Wang
microRNAs (miRNAs) have been demonstrated to contribute to tumor progression and metastasis, and have been proposed to be key regulators of diverse biological processes. In this study, we report that miR-4295 is deregulated in bladder cancer tissues and cell lines. To characterize the role of miR-4295 in bladder cancer cells, we performed functional assays. The overexpression of miR-4295 significantly promoted bladder cancer cell proliferation, colony formation, and migration. Moreover, its downregulation induced cell cycle arrest and apoptosis of bladder cancer cells...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27903751/microdose-induced-drug-dna-adducts-as-biomarkers-of-chemotherapy-resistance-in-humans-and-mice
#4
Maike Zimmermann, Si-Si Wang, Hongyong Zhang, Tzu-Yin Lin, Michael Malfatti, Kurt Haack, Ted Ognibene, Hongyuan Yang, Susan Airhart, Kenneth W Turteltaub, George D Cimino, Clifford G Tepper, Alexandra Drakaki, Karim Chamie, Ralph de Vere White, Chong-Xian Pan, Paul T Henderson
We report progress on predicting tumor response to platinum-based chemotherapy with a novel mass spectrometry approach. Fourteen bladder cancer patients were administered one diagnostic microdose each of [14C]carboplatin (1% of the therapeutic dose). Carboplatin-DNA adducts were quantified by accelerator mass spectrometry (AMS) in blood and tumor samples collected within 24 hours, and compared to subsequent chemotherapy response. Patients with the highest adduct levels were responders, but not all responders had high adduct levels...
November 30, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27902773/genomic-landscape-of-experimental-bladder-cancer-in-rodents-and-its-application-to-human-bladder-cancer-gene-amplification-and-potential-overexpression-of-cyp2a5-cyp2a6-are-associated-with-the-invasive-phenotype
#5
Kazuhiro Kanemoto, Katsuhiro Fukuta, Noriyasu Kawai, Keiichi Tozawa, Masako Ochiai, Koji Okamoto, Sumiko Ohnami, Hiromi Sakamoto, Teruhiko Yoshida, Yae Kanai, Masaru Katoh, Takahiro Yasui, Kenjiro Kohri, Tadao Kakizoe, Hitoshi Nakagama
Non-muscle invasive (superficial) bladder cancer is a low-grade malignancy with good prognosis, while muscle invasive (invasive) bladder cancer is a high-grade malignancy with poor prognosis. N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) induces superficial bladder cancers with papillary morphology in rats and invasive bladder cancers with infiltrating phenotype in mice. In this study, we analyzed genomic landscapes of rodent BBN-induced bladder cancers using array-based comparative genomic hybridization (array CGH)...
2016: PloS One
https://www.readbyqxmd.com/read/27896485/biomarkers-for-precision-medicine-in-bladder-cancer
#6
REVIEW
Takahiro Kojima, Koji Kawai, Jun Miyazaki, Hiroyuki Nishiyama
Bladder cancer (BC) is classified as non-muscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC). Because the recurrence and mortality rates of BC are high, suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses are needed. Urinary markers simplify surveillance schedules and improve early detection of tumors, especially in NMIBC. Various markers have been identified at DNA, RNA, and protein levels with different sensitivities and specificities. Several biomarkers show a higher sensitivity than urinary cytology, but they are not accurate enough to replace it...
November 29, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27896277/prediction-of-bacillus-calmette-guerin-response-in-patients-with-bladder-cancer-after-transurethral-resection-of-bladder-tumor-by-using-genetic-variation-based-on-genomic-studies
#7
REVIEW
Ning Zhang, Guangliang Jiang, Xu Liu, Rong Na, Xiang Wang, Jianfeng Xu
Purpose. We aimed to comprehensively review contemporary literature on genetic and epigenetic biomarkers associated with the prediction of Bacillus Calmette-Guerin (BCG) response after the transurethral resection of a bladder tumor and to discuss the application of these biomarkers in precision cancer care for bladder cancer. Method. We performed a systematic review of published literatures in the databases PubMed and Embase by using the following key words: bladder cancer, BCG, gene, and methylation. Studies associated with cell lines, animal models, and muscle invasive bladder cancer were excluded...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27894096/shed-urinary-alcam-is-an-independent-prognostic-biomarker-of-three-year-overall-survival-after-cystectomy-in-patients-with-bladder-cancer
#8
Shanna A Arnold Egloff, Liping Du, Holli A Loomans, Alina Starchenko, Pei-Fang Su, Tatiana Ketova, Paul B Knoll, Jifeng Wang, Ahmed Q Haddad, Oluwole Fadare, Justin M Cates, Yair Lotan, Yu Shyr, Peter E Clark, Andries Zijlstra
Proteins involved in tumor cell migration can potentially serve as markers of invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes adhesion, while shedding of its extracellular domain is associated with migration. We hypothesized that shed ALCAM in biofluids could be predictive of progressive disease. ALCAM expression in tumor (n = 198) and shedding in biofluids (n = 120) were measured in two separate VUMC bladder cancer cystectomy cohorts by immunofluorescence and enzyme-linked immunosorbent assay, respectively...
24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27878359/long-noncoding-rna-gas5-inhibits-malignant-proliferation-and-chemotherapy-resistance-to-doxorubicin-in-bladder-transitional-cell-carcinoma
#9
Hui Zhang, Yan Guo, Yongsheng Song, Chao Shang
PURPOSE: Bladder cancer is the most general malignant cancer in genitourinary system, more than 90% of BCs are bladder transitional cell carcinomas (BTCC). This study aimed to investigate the clinical significance of growth arrest-specific 5 (GAS5) gene and its regulatory effects of malignant proliferation and chemotherapy resistance to doxorubicin in BTCC cells. METHODS: The expression of GAS5 was detected by quantitative real-time PCR. Statistical analysis was used to determine the relationship between GAS5 expression and clinical features and the prognostic value of GAS5 for disease free survival...
November 22, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27872478/circulating-tumour-cells-as-biomarkers-of-prostate-bladder-and-kidney-cancer
#10
REVIEW
Michael A Gorin, James E Verdone, Emma van der Toom, Trinity J Bivalacqua, Mohamad E Allaf, Kenneth J Pienta
Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide...
November 22, 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27870887/epidermal-growth-factor-receptor-and-ki-67-as-predictive-biomarkers-identify-patients-who-will-be-more-sensitive-to-intravesical-instillations-for-the-prevention-of-bladder-cancer-recurrence-after-radical-nephroureterectomy
#11
Xingbo Long, Xiongbing Zu, Yuan Li, Wei He, Xiheng Hu, Shiyu Tong, Zhi Wang, Minfeng Chen, Lin Qi
BACKGROUND: To date, prophylactic intravesical chemotherapy after radical nephroureterectomy is one of the few available treatments that effectively prevent secondary bladder cancer. However, treating all patients with prophylactic intravesical chemotherapy is excessive for patients who are at a low risk or insensitive to the treatment. Thus, to guide individualized clinical treatment, in addition to identifying patients who are at risk of bladder cancer recurrence, it is equally necessary to identify the patients who will benefit the most from prophylactic, postoperative intravesical instillation therapy...
2016: PloS One
https://www.readbyqxmd.com/read/27863434/a-microrna-biomarker-panel-for-the-non-invasive-detection-of-bladder-cancer
#12
Virginia Urquidi, Mandy Netherton, Evan Gomes-Giacoia, Daniel J Serie, Jeanette Eckel-Passow, Charles J Rosser, Steve Goodison
The development of accurate, non-invasive urinary assays for bladder cancer would greatly facilitate the detection and management of a disease that has a high rate of recurrence and progression. In this study, we employed a discovery and validation strategy to identify microRNA signatures that can perform as a non-invasive bladder cancer diagnostic assay. Expression profiling of 754 human microRNAs (TaqMan low density arrays) was performed on naturally voided urine samples from a cohort of 85 subjects of known bladder disease status (27 with active BCa)...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27863388/comprehensive-analysis-of-aberrantly-expressed-profiles-of-lncrnas-and-mirnas-with-associated-cerna-network-in-muscle-invasive-bladder-cancer
#13
Hanbo Wang, Leilei Niu, Shaobo Jiang, Jing Zhai, Ping Wang, Feng Kong, Xunbo Jin
Although initially thought to be transcriptional noise, long noncoding RNAs (lncRNAs) are gaining increased attention in human cancers as its diversity function. At present, lncRNAs are regarded as the main part of competing endogenous RNA (ceRNA) network due to its regulation on protein-coding gene expression by acting as miRNA sponges. However, functional roles of lncRNA-mediated ceRNAs in muscle-invasive bladder cancer remain unclear. To clarify relevant potential mechanisms, here we comprehensively compared the expression profiles of mRNAs, lncRNAs and miRNAs between 322 muscle-invasive bladder cancer tissues and 19 non-tumor bladder tissues, based on the Cancer Genome Atlas (TCGA)...
November 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27846884/future-perspectives-in-melanoma-research-meeting-report-from-the-melanoma-bridge-napoli-december-1st-4th-2015
#14
Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A Davies, Sandra Demaria, Reinhard Dummer, Alexander M Eggermont, Soldano Ferrone, Yang Xin Fu, Thomas F Gajewski, Claus Garbe, Veronica Huber, Samir Khleif, Michael Krauthammer, Roger S Lo, Giuseppe Masucci, Giuseppe Palmieri, Michael Postow, Igor Puzanov, Ann Silk, Stefani Spranger, David F Stroncek, Ahmad Tarhini, Janis M Taube, Alessandro Testori, Ena Wang, Jennifer A Wargo, Cassian Yee, Hassane Zarour, Laurence Zitvogel, Bernard A Fox, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin
The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's disease...
November 15, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27845906/specific-micro-rna-expression-patterns-distinguish-the-basal-and-luminal-subtypes-of-muscle-invasive-bladder-cancer
#15
Andrea E Ochoa, Woonyoung Choi, Xiaoping Su, Arlene Siefker-Radtke, Bogdan Czerniak, Colin Dinney, David J McConkey
The roles of non-coding RNAs in controlling clinical and biological heterogeneity in bladder cancer remain unclear. We used TCGA's published dataset (n = 405 tumors) as a discovery cohort and created a new validation cohort to define the miRNA expression patterns in the basal and luminal molecular subtypes of muscle-invasive bladder cancer (MIBC). We identified 63 miRNAs by PAM, which optimally identified basal and luminal tumors. The targets of the top luminal miRNAs were activators of EMT (ZEB1, ZEB2) and basal subtype transcription (IL-6, EGFR, STAT3), whereas the targets of the top basal miRNAs were involved in adipogenesis pathways and luminal breast cancer (ERBB2, ERBB3)...
November 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27836246/emerging-role-of-immunotherapy-in-urothelial-carcinoma-immunobiology-biomarkers
#16
REVIEW
Randy F Sweis, Matthew D Galsky
Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette-Guerin was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and patients with bladder cancer finally have new active immunotherapeutic drugs on the horizon. Anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) therapy has shown impressively durable responses in urothelial bladder cancer (UBC), but the reported response rates warrant improvement...
December 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27830363/dysregulated-expression-of-homebox-gene-hoxa13-is-correlated-with-the-poor-prognosis-in-bladder-cancer
#17
Haiyi Hu, Yuebing Chen, Sheng Cheng, Gonghui Li, Zhigen Zhang
BACKGROUND: The homeobox (HOX) genes have been implicated playing important roles in many human cancers. HOXA13 is a member of HOX genes that encode transcription factors regulating embryonic development and cell fate. In the present study, we aimed to investigate the expression and prognostic significance of HOXA13 in bladder cancer. METHODS: Immunohistochemical staining was initially performed to screen the differentially expressed HOXA13 between bladder cancer tissues and paired adjacent non-cancerous tissues...
November 9, 2016: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/27822480/pretreatment-neutrophil-to-lymphocyte-ratio-can-predict-the-prognosis-in-bladder-cancer-patients-who-receive-gemcitabine-and-nedaplatin-therapy
#18
Shinji Ohtake, Takashi Kawahara, Ryo Kasahara, Hiroki Ito, Kimito Osaka, Yusuke Hattori, Jun-Ichi Teranishi, Kazuhide Makiyama, Nobuhiko Mizuno, Susumu Umemoto, Yasuhide Miyoshi, Noboru Nakaigawa, Hiroshi Miyamoto, Masahiro Yao, Hiroji Uemura
Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy. Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27816403/a-review-of-the-pd-1-pd-l1-checkpoint-in-bladder-cancer-from-mediator-of-immune-escape-to-target-for-treatment
#19
REVIEW
Tian C Zhou, Alexander I Sankin, Steven A Porcelli, David S Perlin, Mark P Schoenberg, Xingxing Zang
PURPOSE: Recent observations have focused attention on the means that human tumors employ to evade host defense systems critical to immune surveillance. The concepts of immunotherapy are familiar to urologists because of the use of bacillus Calmette-Guérin in bladder cancer. Research demonstrating the importance of checkpoint inhibitors in suppressing immune responses against tumors has heightened interest in immunotherapy at a time when there is a need for alternatives to bacillus Calmette-Guérin...
November 2, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27814275/detection-of-bladder-cancer-in-urine-sediments-by-a-hypermethylation-panel-of-selected-tumor-suppressor-genes
#20
Michaƚ Pietrusiński, Ƚukasz Képczyński, Adam Jédrzejczyk, Edyta Borkowska, Magdalena Traczyk-Borszyńska, Maria Constantinou, Bogdan Kaƚużewski, Maciej Borowiec
BACKGROUND: Promoter hypermethylation can be a useful biomarker for early detection and prognosis of bladder cancer, monitoring response to treatment and complement classical diagnostic procedures. OBJECTIVE: The molecular test was performed on DNA from bladder cancer cells in voided urine samples, tumor tissue DNA and normal control DNAs. We aimed to assess the diagnostic potential of epigenetic changes in urine DNA from bladder cancer cases at various clinico-pathological stages of the disease...
October 28, 2016: Cancer Biomarkers: Section A of Disease Markers
keyword
keyword
91964
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"